Infectious Complications in Critically Ill Liver Failure Patients

Abstract

Infections remain a leading cause of morbidity and mortality among patients with liver failure. A number of factors, including relative immune dysfunction and systemic inflammation, bacterial translocation, gut dysbiosis, small intestine bacterial overgrowth, altered bile acid pools, and changes in pH due to acid suppression, contribute to the high rates of infection in this population. Though a range of infections can complicate the course of cirrhotic patients, spontaneous bacterial peritonitis (SBP), cholangitis, and cholecystitis in addition to other infections (i.e. pneumonia, urinary tract infection, bacteremia, and Clostridioides difficile colitis) are more common in this population and will be reviewed in this article. Preventative strategies are directed at minimizing the risk of SBP through the use of targeted antimicrobial prophylaxis. Lastly, the critically ill cirrhotic patient may present with an acute need for liver transplantation. Thus, careful assessment for ongoing infection should be performed and treated to optimize outcomes of transplant, if needed.

Keywords

cirrhosis - spontaneous bacterial peritonitis - cholangitis - cholecystitis - pneumonia - UTI - bacteremia and C. difficile colitis

^* Co-first authors.

• References

• 1 Jalan R, Yurdaydin C, Bajaj JS. , et al; World Gastroenterology Organization Working Party Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014; 147 (01) 4-10
• 2 Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55 (03) 965-967
• 3 Moreau R, Jalan R, Gines P. , et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
• 4 Sarin SK, Kedarisetty CK, Abbas Z. , et al; APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8 (04) 453-471
• 5 Gustot T, Fernandez J, Garcia E. , et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015; 62 (01) 243-252
• 6 Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology 2016; 64 (06) 2165-2172
• 7 Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013; 369 (26) 2525-2534
• 8 Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008; 8 (11) 698-709
• 9 Shi Y, Yang Y, Hu Y. , et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015; 62 (01) 232-242
• 10 Dionigi E, Garcovich M, Borzio M. , et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol 2017; 112 (04) 588-596
• 11 Fernández J, Navasa M, Gómez J. , et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35 (01) 140-148
• 12 Arvaniti V, D'Amico G, Fede G. , et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139 (04) 1246-1256 , 1256.e1–1256.e5
• 13 Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369 (21) 2063
• 14 Jalan R, Fernandez J, Wiest R. , et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (06) 1310-1324
• 15 Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50 (06) 2022-2033
• 16 Clària J, Arroyo V, Moreau R. The acute-on-chronic liver failure syndrome, or when the innate immune system goes astray. J Immunol 2016; 197 (10) 3755-3761
• 17 Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015; 63 (05) 1272-1284
• 18 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348 (02) 138-150
• 19 Fernández J, Acevedo J, Wiest R. , et al; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018; 67 (10) 1870-1880
• 20 Cirera I, Bauer TM, Navasa M. , et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34 (01) 32-37
• 21 Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60 (01) 197-209
• 22 Bajaj JS, Heuman DM, Hylemon PB. , et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (05) 940-947
• 23 Chen Y, Guo J, Qian G. , et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 2015; 30 (09) 1429-1437
• 24 Shah A, Shanahan E, Macdonald GA. , et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis 2017; 37 (04) 388-400
• 25 Bauer TM, Schwacha H, Steinbrückner B. , et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97 (09) 2364-2370
• 26 Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci 1997; 42 (04) 738-742
• 27 Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28 (05) 1187-1190
• 28 Kakiyama G, Pandak WM, Gillevet PM. , et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58 (05) 949-955
• 29 Lachar J, Bajaj JS. Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis. Semin Liver Dis 2016; 36 (04) 327-330
• 30 Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153 (01) 35-48
• 31 O'Leary JG, Reddy KR, Wong F. , et al; North American Consortium for the Study of End-Stage Liver Disease. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13 (04) 753-9 .e1, 2
• 32 Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis 2016; 48 (04) 353-359
• 33 Bajaj JS, Ananthakrishnan AN, Hafeezullah M. , et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105 (01) 106-113
• 34 Levesque E, Hoti E, Azoulay D. , et al. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012; 56 (01) 95-102
• 35 Seymour CW, Gesten F, Prescott HC. , et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017; 376 (23) 2235-2244
• 36 Arabi YM, Dara SI, Memish Z. , et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology 2012; 56 (06) 2305-2315
• 37 Bajaj JS, O'Leary JG, Reddy KR. , et al; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56 (06) 2328-2335
• 38 Fernández J, Acevedo J, Castro M. , et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55 (05) 1551-1561
• 39 Bartoletti M, Giannella M, Caraceni P. , et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol 2014; 61 (01) 51-58
• 40 Thulstrup AM, Sørensen HT, Schønheyder HC, Møller JK, Tage-Jensen U. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000; 31 (06) 1357-1361
• 41 Bartoletti M, Giannella M, Lewis R. , et al; ESGBIS/BICHROME Study Group. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect 2018; 24 (05) 546.e1-546 .e8
• 42 Pappas PG, Kauffman CA, Andes DR. , et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62 (04) e1 –e50
• 43 Mermel LA, Allon M, Bouza E. , et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 (01) 1-45
• 44 Hung TH, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. The risk for bacterial endocarditis in cirrhotic patients: a population-based 3-year follow-up study. Int J Infect Dis 2013; 17 (06) e391 –e393
• 45 Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence 2016; 7 (03) 309-319
• 46 Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18 (03) 353-358
• 47 Hung TH, Tseng CW, Hsieh YH, Tseng KC, Tsai CC, Tsai CC. High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol 2013; 13: 25
• 48 Kalil AC, Metersky ML, Klompas M. , et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) 575-582
• 49 Mandell LA, Wunderink RG, Anzueto A. , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl (Suppl. 02) S27 –S72
• 50 Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; ;( (08) CD007577
• 51 Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144 (06) 1759-1767
• 52 Shen KR, Bribriesco A, Crabtree T. , et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017; 153 (06) e129 –e146
• 53 Chen CH, Shih CM, Chou JW. , et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int 2011; 31 (03) 417-424
• 54 Xiol X, Castellví JM, Guardiola J. , et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996; 23 (04) 719-723
• 55 Xiol X, Castellote J, Baliellas C. , et al. Spontaneous bacterial empyema in cirrhotic patients: analysis of eleven cases. Hepatology 1990; 11 (03) 365-370
• 56 Allam NAH. Spontaneous bacterial empyema in liver cirrhosis: an underdiagnosed pleural complication. Saudi J Gastroenterol 2008; 14 (01) 43-45
• 57 Lam ST, Johnson ML, Kwok RM, Bassett JT. Spontaneous bacterial empyema: not your average empyema. Am J Med 2014; 127 (07) e9 –e10
• 58 Bal CK, Bhatia V, Kumar S. , et al. Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series. Indian J Gastroenterol 2014; 33 (02) 178-182
• 59 Marzano A, Marengo A, Ruggiero T. , et al. Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection. J Med Virol 2013; 85 (01) 1-7
• 60 Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis - Relevance of acute kidney injury and comorbidities. Liver Int 2013; 33 (02) 220-230
• 61 Hooton TM, Bradley SF, Cardenas DD. , et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (05) 625-663
• 62 Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56 (Suppl (Suppl. 01) S1 –S12
• 63 Gupta K, Hooton TM, Naber KG. , et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52 (05) e103 –e120
• 64 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
• 65 Kim JJ, Tsukamoto MM, Mathur AK. , et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol 2014; 109 (09) 1436-1442
• 66 Runyon BA. ; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57 (04) 1651-1653
• 67 Chinnock B, Afarian H, Minnigan H, Butler J, Hendey GW. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med 2008; 52 (03) 268-273
• 68 Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001; 96 (04) 1232-1236
• 69 Niu B, Kim B, Limketkai BN. , et al. Mortality from spontaneous bacterial peritonitis among hospitalized patients in the USA. Dig Dis Sci 2018; 63 (05) 1327-1333
• 70 Toledo C, Salmerón JM, Rimola A. , et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17 (02) 251-257
• 71 Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther 2014; 40 (01) 105-112
• 72 Schwabl P, Bucsics T, Soucek K. , et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver Int 2015; 35 (09) 2121-2128
• 73 Tandon P, Kumar D, Seo YS. , et al. The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Am J Gastroenterol 2013; 108 (09) 1473-1479
• 74 Felisart J, Rimola A, Arroyo V. , et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5 (03) 457-462
• 75 Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100 (06) 1737-1742
• 76 Sort P, Navasa M, Arroyo V. , et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
• 77 Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990; 98 (01) 127-133
• 78 European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65 (01) 146-181
• 79 Frankel HL, Kirkpatrick AW, Elbarbary M. , et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients-part I: general ultrasonography. Crit Care Med 2015; 43 (11) 2479-2502
• 80 Simorov A, Ranade A, Parcells J. , et al. Emergent cholecystostomy is superior to open cholecystectomy in extremely ill patients with acalculous cholecystitis: a large multicenter outcome study. Am J Surg 2013; 206 (06) 935-940 , discussion 940–941
• 81 Kimura Y, Takada T, Kawarada Y. , et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14 (01) 15-26
• 82 Lai EC, Mok FP, Tan ES. , et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med 1992; 326 (24) 1582-1586
• 83 Rösch J, Hanafee W, Snow H, Barenfus M, Gray R. Transjugular intrahepatic portacaval shunt. An experimental work. Am J Surg 1971; 121 (05) 588-592
• 84 Rössle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998; 18 (02) 73-89
• 85 Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115 (01) 110-115
• 86 Navaratnam AM, Grant M, Banach DB. Endotipsitis: a case report with a literature review on an emerging prosthetic related infection. World J Hepatol 2015; 7 (04) 710-716
• 87 Mizrahi M, Adar T, Shouval D, Bloom AI, Shibolet O. Endotipsitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management. Liver Int 2010; 30 (02) 175-183
• 88 Magill SS, Edwards JR, Bamberg W. , et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370 (13) 1198-1208
• 89 Lessa FC, Mu Y, Bamberg WM. , et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372 (09) 825-834
• 90 Loo VG, Bourgault A-M, Poirier L. , et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365 (18) 1693-1703
• 91 McDonald LC, Gerding DN, Johnson S. , et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66 (07) 987-994
• 92 Bauer MP, Hensgens MP, Miller MA. , et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 2012; 55 (Suppl (Suppl. 02) S149-S153
• 93 Johnson S, Louie TJ, Gerding DN. , et al; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59 (03) 345-354
• 94 Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45 (03) 302-307
• 95 Louie TJ, Miller MA, Mullane KM. , et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364 (05) 422-431
• 96 Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3: CD004610
• 97 Van Hise NW, Bryant AM, Hennessey EK, Crannage AJ, Khoury JA, Manian FA. Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis 2016; 63 (05) 651-653
• 98 Bajaj JS, Rajender Reddy K, Tandon P. , et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol 2018; 113 (04) 556-563
• 99 Bassetti M, Peghin M, Carnelutti A. , et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Med 2017; 43 (04) 509-518
• 100 Nadim MK, Durand F, Kellum JA. , et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016; 64 (03) 717-735
• 101 Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000; 182 (02) 526-533
• 102 Bellot P, García-Pagán JC, Francés R. , et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52 (06) 2044-2052
• 103 Cervoni JP, Thévenot T, Weil D. , et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012; 56 (06) 1299-1304
• 104 Lazzarotto C, Ronsoni MF, Fayad L. , et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013; 12 (04) 599-607
• 105 Agiasotelli D, Alexopoulou A, Vasilieva L. , et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int 2017; 37 (04) 576-582
• 106 Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (05) 426-435
• 107 de Jong E, van Oers JA, Beishuizen A. , et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16 (07) 819-827
• 108 Yang SK, Xiao L, Zhang H. , et al. Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: a systematic review and meta-analysis. BMC Infect Dis 2014; 14: 452
• 109 Pronovost PJ, Weaver SJ, Berenholtz SM. , et al. Reducing preventable harm: observations on minimizing bloodstream infections. J Health Organ Manag 2017; 31 (01) 2-9
• 110 Saint S, Greene MT, Kowalski CP, Watson SR, Hofer TP, Krein SL. Preventing catheter-associated urinary tract infection in the United States: a national comparative study. JAMA Intern Med 2013; 173 (10) 874-879
• 111 Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med 2003; 138 (06) 494-501
• 112 Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis 2014; 59 (Suppl (Suppl. 03) S97 –S100
• 113 Zuccaro V, Columpsi P, Sacchi P, Lucà MG, Fagiuoli S, Bruno R. Antibiotic stewardship and empirical antibiotic treatment: how can they get along?. Dig Liver Dis 2017; 49 (06) 579-584
• 114 Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009; 7 (04) 487-493
• 115 Fernández J, Ruiz del Arbol L, Gómez C. , et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
• 116 Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29 (06) 1655-1661
• 117 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. , et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34 (05) 509-518
• 118 Titó L, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8 (01) 27-31
• 119 Ginés P, Rimola A, Planas R. , et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4 Pt 1): 716-724
• 120 Avery RK, Snydman DR. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35 (12) 1513-1519
• 121 Fischer SA, Lu K. ; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant 2013; 13 (Suppl (Suppl. 04) 9-21
• 122 Subramanian AK, Morris MI. ; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl (Suppl. 04) 68-76
• 123 Schwartz BS, Mawhorter SD. ; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 280-303